Cargando…
TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy
The development of targeted therapies for both germline and somatic DNA mutations has increased the need for molecular profiling assays to determine the mutational status of specific genes. Moreover, the potential of off-label prescription of targeted therapies favors classifying tumors based on DNA...
Autores principales: | Gray, Phillip N., Vuong, Huy, Tsai, Pei, Lu, Hsaio-Mei, Mu, Wenbo, Hsuan, Vickie, Hoo, Jayne, Shah, Swati, Uyeda, Lisa, Fox, Susanne, Patel, Harshil, Janicek, Mike, Brown, Sandra, Dobrea, Lavinia, Wagman, Lawrence, Plimack, Elizabeth, Mehra, Ranee, Golemis, Erica A., Bilusic, Marijo, Zibelman, Matthew, Elliott, Aaron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356550/ https://www.ncbi.nlm.nih.gov/pubmed/27626691 http://dx.doi.org/10.18632/oncotarget.11910 |
Ejemplares similares
-
TumorNext-Lynch-MMR: a comprehensive next generation sequencing assay for the detection of germline and somatic mutations in genes associated with mismatch repair deficiency and Lynch syndrome
por: Gray, Phillip N., et al.
Publicado: (2018) -
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
por: Bilusic, Marijo, et al.
Publicado: (2022) -
Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020) -
Anti-angiogenesis in prostate cancer: knocked down but not out
por: Bilusic, Marijo, et al.
Publicado: (2014) -
Approved checkpoint inhibitors in bladder cancer: which drug should
be used when?
por: Ghatalia, Pooja, et al.
Publicado: (2018)